Complexes formed by mutant p53 and their roles in breast cancer by Bellazzo, Arianna et al.
© 2018 Bellazzo et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Breast Cancer - Targets and Therapy 2018:10 101–112
Breast Cancer - Targets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
101
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/BCTT.S145826
Complexes formed by mutant p53 and their roles 
in breast cancer
Arianna Bellazzo1
Daria Sicari1,2
Elena Valentino1,2
Giannino Del Sal1,2
Licio Collavin1,2
1National Laboratory CIB (LNCIB), 
AREA Science park, Trieste, Italy; 
2Department of Life Sciences, 
University of Trieste, Trieste, Italy
Abstract: Breast cancer is the most frequently diagnosed malignancy in women, and muta-
tions in the tumor suppressor p53 are commonly detected in the most aggressive subtypes. The 
majority of TP53 gene alterations are missense substitutions, leading to expression of mutant 
forms of the p53 protein that are frequently detected at high levels in cancer cells. P53 mutants 
not only lose the physiological tumor-suppressive activity of the wild-type p53 protein but also 
acquire novel powerful oncogenic functions, referred to as gain of function, that may actively 
confer a selective advantage during tumor progression. Some of the best-characterized onco-
genic activities of mutant p53 are mediated by its ability to form aberrant protein complexes 
with other transcription factors or proteins not directly related to gene transcription. The set of 
cellular proteins available to interact with mutant p53 is dependent on cell type and extensively 
affected by environmental signals, so the prognostic impact of p53 mutation is complex. Specific 
functional interactions of mutant p53 can profoundly impact homeostasis of breast cancer cells, 
reprogramming gene expression in response to specific extracellular inputs or cell-intrinsic 
conditions. The list of protein complexes involving mutant p53 in breast cancer is continu-
ously growing, as is the number of oncogenic phenotypes in which they could be involved. In 
consideration of the functional impact of such complexes, key interactions of mutant p53 may 
be exploited as potential targets for development of therapies aimed at defusing the oncogenic 
potential of p53 mutation.
Keywords: protein–protein interactions, mutant p53 gain of function, targeted therapy, cancer-
cell homeostasis
Introduction
The TP53 gene is the most frequent target for mutation in human cancer, and TP53 
mutations are associated with malignancy and adverse prognosis.1,2 According to the 
Catalogue of Somatic Mutation in Cancer (COSMIC), approximately 23% of human 
breast cancers display TP53 mutation, and this value oscillates from >80% in basal-like 
to <15% in luminal A subtypes.3,4 The critical implication of TP53 gene mutation in 
development of breast cancer is reinforced by the frequent occurrence of this cancer 
in Li–Fraumeni syndrome, a hereditary tumor-predisposing disorder associated with 
germ-line TP53 mutations.5
The predominance of mutations with respect to deletions indicates that TP53 muta-
tions may confer a selective advantage during cancer development. Tumor-associated 
TP53 alterations are most frequently missense mutations, leading to substitution of 
a single amino acid in the p53 protein.2,6 The majority of missense mutations occur 
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within the DNA-binding domain of p53, impairing its 
sequence-specific interaction with target gene promoters.2 
This implies loss of p53-transcriptional activity and related 
oncosuppressive responses. Because p53 normally acts as 
a tetramer, mutant p53 (mutp53) proteins may also act as 
dominant inhibitors of a remaining wild-type p53 allele. 
However, most importantly, mutations in the structured core 
of p53 can have significant consequences on its capability to 
establish novel protein interactions, and this may be a crucial 
step in the acquisition of oncogenic properties by mutp53, a 
phenomenon defined as “gain of function”, or GOF.6
Mutp53 protein complexes as mediators 
of breast cancer aggressiveness
In breast cancer, mechanisms supporting primary tumor 
growth and survival, as well as features required for metas-
tasis to secondary sites, can all be linked to mutp53 GOF.6,7 
Many such oncogenic functions have been ascribed to 
interactions between mutp53 and other transcription factors, 
determining specific gene-expression programs. In addition, 
some mutp53 oncogenic activities rely on its association with 
partners not involved in gene transcription. In any case, for-
mation of protein–protein interactions appear to be a crucial 
element of mutp53 GOF.
One compelling open question, therefore, regards whether 
different mutp53 mutants might have distinctive functions, 
depending on the specific conformational change imposed 
by each mutation. In fact, different p53 missense mutants 
may have different affinity for interacting proteins, generat-
ing phenotypic differences in their GOF.8 Indeed, knock-in 
mice expressing different p53 mutants display distinct cancer 
phenotypes, confirming that missense p53 mutations may 
have diverse biological effects.9,10 It should also be considered 
that a sizeable number of tumor-associated TP53 mutations 
fall outside the DNA-binding domain, potentially affecting 
protein conformation, tetramerization, and/or posttransla-
tional modifications, impinging on mutp53 interactions in 
additional ways. Nonetheless, evidence has demonstrated 
that different p53 mutants can interact with the same tran-
scription factors or proteins, activating identical target genes, 
and modulating the same signaling pathways.8,11 Therefore, it 
remains an open challenge to define the specific impact of p53 
mutations found in real tumors and to distinguish such activ-
ity from a more general pro-oncogenic action that depends 
on features common to all “misfolded” mutp53 proteins.
The accumulation of mutp53 observed in malignancies 
is also critical for its functions, suggesting that not only 
the altered conformation but also the increased amounts of 
mutp53 favor formation of nonphysiological complexes that 
contribute to the oncogenic phenotype.12 In line with this 
concept, various groups have provided evidence of prion-
like behavior of cancer-associated p53 mutants: mutp53 
accumulates in heterogeneous protein complexes composed 
of amorphous aggregates, oligomers, and amyloid-like fibrils 
that are involved in breast cancer progression.13,14 Several 
proteins found in mutp53 aggregates are involved in onco-
genic processes, including cell metabolism, inflammatory 
response, RNA processing, and regulation of proteotoxic 
and oxidative stresses.15
Whatever the mechanism and potential elements of 
specificity, it is legitimate to generalize that interaction 
with mutp53 can either potentiate the oncogenic activity of 
tumor promoting factors or destabilize the tumor suppressive 
action of oncosuppressors.6,8 There is a significant amount of 
literature on protein interactions of mutp53 in cancer, many 
of which can mechanistically explain some aspects of the 
GOF. Here, we focus exclusively on mutp53 interactions 
that have been detected in breast cancer models (Table 1). 
More general features of mutp53 GOF have been recently 
reviewed elsewhere.8,16–18
By forming complexes with other 
transcription factors, mutp53 
reprograms gene expression in 
cancer cells
It is well established that mutp53 can profoundly alter the 
gene-expression profile of the cancer cell.6,18 Various evidence 
has suggested that mutp53 binds DNA, thus raising the pos-
sibility that some mutp53 proteins can recognize a unique 
response element.19 Nevertheless, a consensus sequence for 
mutp53 binding has not been identified.6,20 Rather, mutp53 
has been found to interact with other transcription factors, 
enhancing or subverting their normal activity, thereby chang-
ing the expression profile of their target genes.
For example, in human breast cancer cells, mutp53 bind-
ing with the transcription factor E2F1 leads to transcriptional 
activation of ID4, which in turn promotes neovascularization 
of breast tumor tissue.21 Similarly, mutp53 binding with E2F4 
causes downregulation of genes involved in DNA repair,22 
promoting cell survival and escaping apoptosis. Perhaps 
the best-characterized transcriptional partner of mutp53 is 
NFY. Studies in human breast cancer cell lines have shown 
that mutp53 interaction with NFY neutralizes the cell-cycle 
checkpoint following low levels of DNA damage.23 Under 
these conditions, DNA TopBP1 recruits mutp53 and the cofac-
tor p300 to mediate their binding with NFY, and  stimulates 
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transcription of genes involved in chemoresistance, cell-cycle 
progression, and cell proliferation.24 More recently, Krishnan 
et al demonstrated that the oncogenic coregulator PELP1 is 
necessary for the efficient recruitment of mutp53 on NFY 
target genes upon DNA damage.25 In triple-negative breast 
cancer (TNBC) cell models, knockdown of PELP1 improves 
the chemotherapeutic response, inhibiting cell-cycle progres-
sion and activating apoptosis (Figure 1A).
A molecular circuit involving mutp53–NFY links lipid 
metabolism to the control of cell proliferation and tumor-
tissue architecture (Figure 1B). This involves interaction 
with another transcription factor, YAP, a master regulator of 
tissue growth; formation of a YAP–NFY–mutp53 complex 
in human cancer cells drives transcription of prosurvival and 
proliferative genes, also promoting acquisition of invasive 
features.26 The function of this complex in breast cancer is 
finely regulated by lipid metabolism and mechanotransduc-
tion. First, both in physiology and malignancy, the activation 
of YAP is robustly controlled by the mevalonate pathway.27 
Inhibition of the mevalonate pathway by pharmacological 
treatment with statins, a class of drugs used to lower cellular 
cholesterol levels, counteracts YAP/TAZ nuclear activity, 
Table 1 List of published mutant p53 interactions and their functional impact
Interactor Biological effect Reference(s)
Transcription factors: positive regulation/cooperation
E2F1 ID4-dependent induction of proangiogenic mediators; enhanced angiogenesis 21
E2F4 Downregulation of DNA-repair genes; less efficient DNA-damage repair 22
ETS1 Upregulation of drug-resistance genes 88
ETS2 Upregulation of nucleotide biosynthesis genes; improved chemoresistance 89, 90
HSF1 Heat-shock gene transcription; enhanced resistance to proteotoxic stress 33
MAFF Repression of secreted IL1Ra; increased IL1 signaling and tumor growth 91
NFY/p300/TopBP1 Upregulation of cell-cycle genes; enhanced chemoresistance and cell survival 23, 24
NFY/YAP Enhanced YAP activity; transcription of proproliferative and prosurvival genes 26
NRF2 Transcription of genes encoding proteasome machinery 30
PELP1 Recruitment of mutp53 on its target genes; chemoresistance 25
SP1 Transcription of ENTPD5; enhanced folding and secretion of N-glycoproteins 35
SREBP2 Transcription of mevalonate pathway and fatty-acid biosynthesis genes; enhanced cell motility and self-
renewal; mutp53 stabilization
27, 29, 87
VDR Altered transcriptional response to vitamin D3; resistance to apoptosis 34
Transcription factors: negative regulation/inhibition
p63 Inhibition of TAp63 transcriptional activity; enhanced invasive phenotype 40, 42, 43
p63–SMAD complex Inhibition of TAp63-target genes (Sharp1/cyclin G2); enhanced invasive phenotype 43
p73 Reprogrammed p73-transcriptional activity; inhibition of apoptosis 37, 48, 49
Mediators of genomic stability and chromatin-remodeling complexes
Mre11
Disruption of Mre11–Rad50–NBS1 (MRN) complex, impaired ATM activation; defective DNA double-
strand break (DSB)-response pathways
55
SWI–SNF complex Enhanced VEGFR2 expression; enhanced VEGFR2 signaling, cell proliferation, and migration 59
Cytoplasmic interactors
AMPK Enhanced aerobic glycolysis in response to energy stress; increased tumor growth and invasion 64
DAB2IP
Enhanced cell invasion and survival in response to inflammatory stimuli; augmented proliferation and 
invasion upon insulin stimulation
62, 63
Rac1
Enhanced Rac1 activity by preventing Rac1 de-SUMOylation; enhanced growth and metastasis of tumor 
xenografts
65
Positive regulators of mutant p53 stability and activity
BAG2/BAG5 Inhibition of mutp53 ubiquitination and degradation by MDM2 75, 76
Pin1 Enhanced mutp53-dependent inhibition of p63; cancer growth and invasion 45
Plk2 Enhanced mutp53–NFY–p300 complex formation; increased expression of cell-cycle genes 77
Pontin Augmented mutp53-transcriptional activity; enhanced cell migration and invasion 79
HSP90 Increased mutp53 stability and accumulation 70
HSP70 Inhibition of mutp53 ubiquitination and degradation by MDM2 74
Negative regulators of mutant p53 stability and activity
ATF3 Prevents mutp53 interaction with p63; reactivates p63 function, with decreased drug resistance 92
CHIP Stimulates mutp53 degradation 68
Mdm2 Stimulates mutp53 degradation 69
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blunting the pro-oncogenic potential of mutp53.26,27 At the 
same time, mutp53 accumulation in breast cancer cells is 
sustained by RhoA geranylgeranylation downstream of the 
mevalonate pathway and by an actin-dependent transduction 
of mechanical inputs, sensing the stiffness of the surrounding 
tissue.28 In breast cancer cells, pharmacological inhibition 
of geranylgeranyl transferase 1 phenocopies the effects of 
statins, counteracting mutp53 GOF.28
Another important functional link between mutp53 and 
cellular lipid homeostasis relies on its capability to boost the 
mevalonate pathway and fatty-acid intermediates, by binding 
the SREBP family of transcription factors, master regulators 
Cell survivalChemoresistance
DNA damage
A B
C D
E F
Lipid restriction Proteotoxic stress
Other inputs
Cell-cycle progression
Cell proliferation
Mevalonate pathway
activation
Cell proliferation
Chemoresistence
Oncogenic
outputs
Proteasome
activation
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Figure 1 Mutant p53 (mutp53) interacts with various transcription factors (TFs) to reprogram gene expression in cancer cells.
Notes: (A) Mutp53 forms a complex with NFY, p300, PELP1, and TopBP1 to control expression of genes involved in cell proliferation and in resistance to DNA-damaging 
drugs.23–25 (B) Mutp53 binds with YAP and NFY on the promoters of genes involved in cell growth and proliferation; both mechanical inputs and activation of the mevalonate 
pathway control formation and activity of this protein complex.26–28,87 (C) By interacting with SREBP2, mutp53 controls expression of enzymes involved in the mevalonate 
pathway, promoting cholesterol and fatty-acid biosynthesis, sustaining disruption of mammary-tissue architecture, and inhibiting mechanisms of mutp53 degradation.27–29,87,93 
(D) By interacting with NRF2, mutp53 controls expression of multiple subunits of the proteasome, alleviating proteotoxic stress and accelerating turnover of cell-cycle 
inhibitors.30 (E) In a complex with HSF1, mutp53 controls expression of chaperones and heat-shock proteins that in turn promote mutp53 stability.33 (F) Mutp53 may interact 
with additional transcription factors, potentially controlling expression of different gene sets, to mediate its oncogenic gain of function.
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of fatty-acid and cholesterol biosynthesis.29 Forming a com-
plex with SREBP2, mutp53 enhances expression of SREBP 
target genes, reprogramming cancer-cell metabolism via 
induction of the mevalonate pathway, leading to the disrup-
tion of normal mammary-tissue architecture.29 In addition, 
the mutp53–SREBP complex indirectly potentiates nuclear 
localization and activation of YAP/TAZ in a positive-feedback 
loop (Figure 1C).27 Therefore, by forming complexes with 
YAP, NFY, and SREBP, mutp53 can coordinate lipid metabo-
lism, responses to mechanical cues (such as stiffness of the 
extracellular matrix), and a global pro-oncogenic transcrip-
tional program, favoring tumor growth and metastasis.
Mutp53 can also affect cellular homeostasis by upregu-
lating proteasome machinery, with a negative impact on 
tumor-suppressive mechanisms. This action relies at least 
in part on its interaction with the transcription factor Nrf2, 
characterized in human TNBC cells (Figure 1D). Upon pro-
tein stress, such as that induced by proteasome inhibition 
or by oxidants, mutp53 binds Nrf2 to enhance transcription 
of proteasome genes. This alleviates the protein load and 
favors proteasomal degradation of tumor-suppressor proteins 
involved in proliferation control and apoptosis, thus result-
ing in a pro-oncogenic response.30 Importantly, Nrf2 acts as 
a master regulator of oxidative stress response. Lisek et al 
very recently reported that mutp53–Nrf2 interaction not only 
promotes expression of proteasome subunits but also coor-
dinates transcription of a specific subset of Nrf2-dependent 
antioxidant-response genes, supporting survival of breast 
cancer cells.31
Interestingly, mutp53 can endow cancer cells with aug-
mented tolerance to proteotoxic stress by activating transcrip-
tion factors that are physiologically inhibited by the wild-type 
p53 protein. For instance, wild-type p53 negatively regulates 
the cytoprotective functions of the heat-shock protein HSF1, 
facilitating the induction of cell senescence upon DNA 
damage.32 In human TNBC cells, via direct interaction with 
HSF1, mutp53 promotes transcription of HSPs and broadly 
enhances oncogenic signals via HSF1 activation, thus provid-
ing survival advantages (Figure 1E).33
Along this line, mutp53 interaction with the zinc-finger 
VDR provides another example of how transcriptional 
complexes involving mutp53 can dramatically subvert cell 
response to various inputs. In fact, mutp53 has been reported 
to bind VDR and p300, and this complex converts the cyto-
toxic effect of vitamin D3 into an antiapoptotic stimulus in 
human breast cancer cells.34
Finally, in human pancreatic and breast cancer cell lines, it 
has been recently shown that mutp53 can be recruited by SP1 
on the promoter of the gene ENTPD5 to induce its expression. 
ENTPD5 is an enzyme involved in N-glycoprotein folding via 
the calnexin–calreticulin cycle in the ER; mutp53-induced 
expression of ENTPD5 may favor or accelerate folding 
and cell-surface localization of prometastatic receptors and 
ligands, eventually supporting tissue remodeling, extracel-
lular matrix invasion, and lung colonization in breast cancer.35
The emerging picture is that mutp53 can control gene 
expression by binding other transcription factors, changing 
their activity or influencing the selection of target genes. It 
is likely that additional such partners of mutp53 will be dis-
covered in the near future, further increasing the complexity 
of its transcriptional impact (Figure 1F).
Binding other p53 family members, 
mutp53 subverts their tumor-
suppressive transcriptional activities
The interaction of mutp53 with transcription factors can 
also be inhibitory. The best-understood example of this 
phenomenon is mutp53 inhibition of other members of the 
p53 family – p63 and p73.36 Multiple studies collectively 
suggest that conformational changes in the p53 core domain 
cause its interaction with p63/p73.37–39 Mutp53 binds DNA 
through p63 interaction, though at sites distinct from those 
that p63 would normally bind.40 Mutp53–p63 association 
impairs TAp63-transcriptional activity, hindering its metas-
tasis-suppressor functions.41–43 The capacity of mutp53 to 
bind and counteract p63 tumor-suppressive function is 
itself controlled at different levels, with the involvement 
of additional partners and intrinsic and extrinsic signals. 
For example, TGFβ acts in concert with oncogenic Ras to 
induce the assembly of a ternary complex in which Smad2 
serves as an essential platform, facilitating the interaction 
between mutp53 and TAp63, in both human and murine 
cell models. This protein complex leads to the inhibition of 
p63-dependent expression of two important suppressors of 
metastasis, Sharp1 and cyclin G2, fostering invasion of tumor 
cells.43 Similarly, phosphorylation-dependent isomerization 
by Pin1 favors mutp53 interaction with TAp63 in TNBC 
cells, contributing to define a proinvasive transcriptional 
program that can stratify breast cancer patients according 
to recurrence-free survival.44,45 Mutp53-mediated suppres-
sion of p63-transcriptional activity also results in enhanced 
RCP-driven recycling of the α
5
β
1
 integrin and EGFR. This 
activates Rho and PKB/Akt to promote cell migration and 
invasion.42 Enhancement of PI3k–Akt signaling mediated by 
integrin/receptor recycling also promotes the activation of 
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WIP, which stimulates the oncogenic phenotype by enhanc-
ing YAP/TAZ stability.46,47
P53 mutants also interact with multiple p73 isoforms,48 
reprogramming their transcriptional activity and counteract-
ing apoptosis.37,49 Various p53 missense mutants (R175H, 
Y220C, and R248W) have been demonstrated to bind 
with p63, and also p73 in human cancer cells, to subvert 
the transactivation of target genes.37,38 In transgenic mice, 
stable expression of mutp53 (R172H) in the mammary gland 
reduces both basal and DNA-damage-induced apoptosis;50 
pharmacological inhibition of mutp53 restores apoptosis 
induction via p73 reactivation.51–53 Finally, a study carried 
out in pancreatic cancer models, but also confirmed in breast 
cancer cells, uncovered a role for mutp53 in enhancing metas-
tasis by preventing the repressive interaction of p73 with the 
transcription factor NFY, thus increasing expression of the 
proinvasive PDGFRβ factor.54
Interacting with chromatin-
associated proteins, mutp53 can 
affect gene expression and genome 
stability
P53 mutants can perturb the DNA-damage response and 
promote breast cancer cell survival also by interacting with 
nuclear proteins that are not sequence-specific transcription 
factors. One noticeable example is the interaction of mutp53 
with the nuclease Mre11. By introducing two different 
mutations into a humanized p53 allele in mice, it has been 
demonstrated that high levels of mutp53 protein disrupt 
formation of the Mre11–Rad50–NBS1 complex at DNA 
double-strand breaks, leading to impaired ATM function 
and accumulation of mutations during proliferation of tumor 
cells.55,56 Accordingly, an increased number of chromosomal 
abnormalities have been observed in breast cancers bearing 
p53 mutations.57,58
Another mutp53 GOF involves direct binding of mutp53 
with the SWI–SNF chromatin-remodeling complex, observed 
in human breast cancer cell lines; via this interaction, hotspot 
p53 mutants might affect chromatin status and gene transcrip-
tion in breast cancer.59 The SWI–SNF complex associates 
genome-wide with transcription-regulatory elements to 
modulate nucleosome occupancy.60 Although the authors 
have only explored the impact of SWI–SNF–mutp53 interac-
tion in potentiating VEGFR2 signaling, SWI/SNF function 
is required at multiple mutp53 target genes, suggesting a 
more general role of this complex in mutp53-dependent 
gene regulation.59
In conclusion, although further studies are required to 
support this concept, p53 mutants may be linked to the 
control of chromatin status and structure, thus affecting the 
gene-expression profile of the cancer cell on multiple levels. 
This could explain why so many genes in tumor cells can 
be affected by the presence of p53 mutations, although the 
precise mechanism for this activity remains to be defined.
By forming complexes with 
cytoplasmic proteins involved in 
signal transduction, mutp53 alters 
the response of cancer cells to 
extracellular or intracellular inputs
Cytoplasm is where different signals are integrated, attenu-
ated, or amplified, and where signaling pathways can talk to 
each other. Some of the GOF activities of mutp53 are medi-
ated by its ability to form aberrant complexes with proteins 
not involved in gene transcription. Particularly interesting 
is mutp53 binding with cytoplasmic mediators of signal 
transduction.
For instance, mutp53 can bind the tumor suppressor 
DAB2IP in the cytoplasm of human breast cancer cells. 
DAB2IP is a cytoplasmic Ras GTPase-activating protein 
that also functions as a signaling scaffold to control the 
cell’s responses to multiple signals.61 The direct binding 
with mutp53 proteins interferes with physiological DAB2IP 
interactions, reprogramming the cell’s response to extrinsic 
inputs. The mutp53–DAB2IP complex facilitates breast can-
cer metastases promoted by inflammatory stimuli, reducing 
TNF-induced activation of the proapoptotic ASK1–JNK axis, 
thereby promoting activation of proinvasive NFκB transcrip-
tion factor (Figure 2A).62 Similarly, mutp53-mediated block 
of DAB2IP functions promotes insulin-induced activation 
of the PI3K–Akt pathway, enhancing cell proliferation 
and invasion in hormone-independent breast and prostate 
cancers (Figure 2B).63 Given the broad impact of DAB2IP 
in modulating signal transduction, it is possible that the 
mutp53–DAB2IP complex may also drive the acquisition 
of an aggressive phenotype in cancer cells exposed to other 
microenvironmental stimuli.
Another example of a cytoplasmic GOF for mutp53, 
observed in head and neck tumors but also confirmed in 
breast cancer models, is represented by the cytoplasmic inter-
action between mutp53 and AMPK. AMPK is an important 
energy sensor that regulates the balance between anabolism 
and catabolism. Under energy-stress conditions, mutp53 
preferentially binds the AMPKα subunit and inhibits AMPK 
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activation, thus leading to impaired metabolic checkpoint, 
increased anabolism, and consequent tumor growth and 
progression (Figure 2C).64
Very recently, Yue et al demonstrated that mutp53 can 
bind members of the monomeric GTPase family of proteins 
in the cytoplasm of multiple human cancer cell lines.65 
Specifically, mutp53 interacts with and activates Rac1, a 
small GTPase that regulates various cellular functions, 
including proliferation, cytoskeletal reorganization, and 
cell mobility. SUMOylation is critical to maintain Rac1 in 
an active GTP-bound form.66 The sumo-specific protease 
SENP1 de-SUMOylates Rac1, leading to its inactivation.67 
Yue et al found that mutp53 interaction with Rac1 inhib-
ited SENP1-mediated Rac1 de-SUMOylation, thereby 
promoting Rac1-dependent tumor growth and metastasis 
(Figure 2D).65
In conclusion, oncogenic conditions that lead to an 
increase in mutp53 protein levels also induce substantial 
cytoplasmic localization of the protein. It is legitimate to 
hypothesize that various nonphysiological protein interac-
tions might occur in the cytoplasm, and the list of nontran-
scriptional complexes that may contribute to mutp53 GOF 
is likely to increase.
Complexes formed by mutp53 
regulate its stability and functions
Factors that bind mutp53 may also promote its stabilization 
and activation, driving its oncogenic GOF. Consequently, 
TNF
A B
C D
TNFR
JNK
DAB2IP
Mutp53
Mutp53
Mutp5
3
Mutp
53
Akt1
NFκB
Invasion
Anabolism
Glycolysis
Lipogenesis
Tumor growth
Tumor arrest
Catabolism
Apoptosis
Insulin
INSR
PI3K
DAB2IP
Rac1 Rac1
DE-SUMOylation
Migration and
invasion
SUMO
SUMO
SENP1
Proliferation
Invasion
Low glucose
Low nutrient
AMPKβ
AMPKα
AMPKγ
Figure 2 Mutant p53 (mutp53) forms complexes with cytoplasmic mediators of signal transduction.
Notes: (A) Mutp53 binds and inhibits the tumor suppressor DAB2IP in the cytoplasm of breast cancer cells, reducing TNF-induced activation of the proapoptotic ASK1–JNK 
axis, simultaneously promoting activation and of proinvasive NFκB transcription factor.62 (B) Mutp53 inhibitory action on DAB2IP promotes insulin-induced activation of the 
PI3K–Akt pathway, enhancing cell proliferation and invasion in hormone-independent breast and prostate cancers.63 (C) Mutp53 binds the AMPKα subunit and inhibits AMPK 
activation upon energy stress. This leads to increased anabolic growth of tumor cells and cancer progression.64 (D) Mutp53 binds the monomeric GTPase Rac1, protecting 
it from SENP1-mediated de-SUMOylation. SUMOylated Rac1 is more active, sustaining tumor growth and dissemination.65
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understanding such interactions could have important clini-
cal implications.
Regulators of mutp53 stability
One important element of the oncogenic activity of mutp53 is 
its accumulation at significant levels in cancer cells. Interest-
ingly, the majority of E3 ubiquitin ligases are shared between 
wild-type and mutp53; mutp53levels, in particular, are con-
trolled through binding with Mdm2, CHIP, and Cop1.68,69 It is 
believed that accumulation of high levels of mutp53 protein 
in cancer cells derives from an acquired capability to avoid 
E3-mediated ubiquitination. For example, mutp53 proteins 
are protected from degradation by the binding of cellular 
chaperones. HSP90 has been shown to protect mutp53 from 
both CHIP- and Mdm2-mediated ubiquitination.70 Mutp53 
forms a ternary complex with MDM2 and HSP90; upon 
DNA damage, MDM2 is released, but mutp53 is retained 
in the HSP90 complex and is protected from degradation.71 
Accordingly, destabilization of this complex favors mutp53 
degradation and drug-induced cytotoxicity in tumor cells.71–73
Also, HSP70 binds mutp53 and partially inhibits Mdm2-
driven ubiquitination.74 In breast cancer cells and in mouse 
embryonic fibroblasts stably expressing exogenous human 
mutp53, elevated levels of HSP70 promote formation of 
nuclear HSP70 aggregates that include mutp53 and p73, lim-
iting p73-dependent induction of apoptosis.74 Analogously, 
BAG2 and BAG5 interact with mutp53 in breast and in other 
cancer cells, favoring accumulation of the mutp53 protein 
and the acquisition of oncogenic properties.75,76
Regulators of mutp53 activity
Research has suggested that mutp53 activity can also be 
modulated by posttranslational modifications. For instance, 
the transcriptional activity of mutp53 is potentiated by the 
action of Plk2. In human cell models, Plk2 binds and phos-
phorylates mutp53 in response to DNA damage, promoting 
formation of the p300–NFY–mutp53 complex on cell-cycle 
genes, thus favoring tumor progression and chemoresis-
tance.77 Intriguingly, mutp53 itself induces the transcription 
of Plk2, thereby potentiating this GOF circuit.77
Similarly, mutp53 function can be regulated by the pro-
lyl isomerase Pin1. In breast cancer cells, Pin1-mediated 
isomerization enhances the oncogenic activity of mutp53, 
possibly by enhancing its interaction with TAp63, and drives 
expression of a mutp53-dependent transcriptional program 
that fosters cancer-cell proliferation and invasion.45 Mutp53 
oncogenic functions can also be regulated by Pontin, an 
AAA+ (adenosine triphosphatase associated with diverse 
cellular activities) ATPase involved in multiple biological 
processes, including cellular energetic metabolism, transcrip-
tion, chromatin remodeling, and DNA-damage response.78,79 
The ATPase activity of Pontin promotes mutp53-mediated 
transcriptional upregulation of multiple genes involved in 
migration, invasion, and anchorage-independent growth of 
tumor cells.79 There are some analogies between the action 
of Pin1 and Pontin on mutp53; the fact that they both require 
catalytic activity raises interesting possibilities to blunt 
mutp53 GOF by development of specific pharmacological 
inhibitors.
Therapeutic approaches targeting 
mutp53 protein complexes
As reviewed here, the oncogenic properties of mutp53 are 
tightly related to its ability to form complexes with other pro-
teins. These can be downstream targets, directly or indirectly 
involved in DNA transcription or signal transduction, or can 
be upstream modulators, controlling mutp53 stability and 
activity. In any case, pharmacological approaches aimed at 
disrupting mutp53 complexes represent an appealing strategy 
for cancer therapy. Such approaches may operate along three 
possible lines of attack: stabilizing mutp53 structure to restore 
its wild-type functions, preventing or disrupting oncogenic 
complexes with specific target proteins, and reducing mutp53 
levels by targeting the axis that determines its accumulation 
and activity (Figure 3).
A variety of compounds that elicit mutp53 destabilization, 
inactivation, or reactivation of wild-type p53 functions have 
been developed.80 PRIMA-1 and its analogue PRIMA-1Met 
can refold various p53 mutants, restoring wild-type DNA 
binding and inducing apoptosis. PRIMA-1Met suppresses 
cancer progression in animal models and is currently under-
going clinical trials. Interestingly, other small molecules, such 
as RETRA and NSC59984, have been shown selectively to 
kill mutp53-bearing cancer cells in a p73-dependent manner: 
these molecules release p73 from the inhibitory interaction 
with mutp53, promoting drug-induced cell death.53,81
Another option is to try to disrupt complexes that are 
involved in mutp53 GOF. For instance, we used a chime-
ric “decoy” protein (GFP-KA2) to displace the mutp53–
DAB2IP complex.62 Expression of such a decoy abolished 
inflammation-driven invasion in vitro and xenograft growth 
and dissemination in breast cancer cell models.62 Similarly, 
expression of the GFP-KA2 decoy blocked insulin-induced 
proliferation and invasion in breast cancer cells.63 These 
results provided a proof of principle that peptide or nucleo-
tide aptamers designed to interfere with aberrant complexes 
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formed by mutp53 may have a putative application in targeted 
therapy of breast cancer malignancy. With the same logic, 
tools designed to prevent mutp53 interaction with crucial 
transcriptional partners, such as NFY, SP1, TAp63, and p73, 
would have useful applications in limiting cancer progression.
Other possible approaches aimed at destabilizing mutp53 
protein complexes involve disruption of mechanisms that 
promote mutp53 stability and activity. For instance, blocking 
the function of HSP90 via 17-AAG or ganetespib promotes 
degradation of p53 mutants, favoring apoptosis induc-
tion in in vivo tumor models.70,82 Ganetespib efficiency is 
under evaluation in clinical trials, with promising results, 
especially in lung carcinoma and in metastatic breast can-
cer.83,84 Similarly, SAHA, a histone deacetylase inhibitor, 
stimulates degradation of mutp53 by inhibiting HDAC6, a 
key positive regulator of HSP90. SAHA treatment disrupts 
HDAC6–HSP90–mutp53 complexes, leading to mutp53 
ubiquitination via MDM2 and CHIP.73 Recently, Wang et 
al demonstrated that in TNBC, SAHA specifically reduces 
the transcription of mutp53 by blocking the activity of the 
HDAC8–YY1 protein complex, with higher cytotoxic effect 
in cancer cells bearing p53 mutations with respect to those 
with wild-type or null p53.85
The Pontin-specific ATPase inhibitor rottlerin also 
gave efficient results on mutp53-bearing tumors, reducing 
cell migration, proliferation, and expression of oncogenic 
mutp53-target genes.79 Similarly, destabilization of mutp53/
Pin1 oncogenic functions by the employment of specific 
Pin1 inhibitors showed powerful tumor suppression in breast 
cancer preclinical models.86
Finally, knowledge of the molecular circuits at the base 
of mutp53 GOF may suggest possible lines of intervention 
that combine drugs targeting mutp53 with drugs target-
ing related molecular pathways. One such example is the 
mutp53–Nrf2 complex that drives expression of proteasome 
subunits, increasing protein turnover in breast cancer cells.30 
In this model, combination of the mutp53-inactivating agent 
PRIMA-1Met with the proteasome inhibitor carfilzomib 
showed high efficacy in reducing primary tumor growth and 
dissemination in mammary fat-pad xenografts.30 Another 
example is provided by the SREBP2–mutp53 complex and 
regulation of mutp53 levels by the mevalonate pathway. In 
fact, treatment with statins, compounds that inhibit HMG-
CoA reductase, induce mutp53 degradation and loss of func-
tion. Accordingly, statins suppress progression of mammary 
tumors bearing p53 mutations in preclinical models.27,28,87
In conclusion, a detailed understanding of the transcrip-
tional and nontranscriptional complexes involving mutp53 is 
an important prerequisite for the development of novel mol-
ecules to target mutp53 oncogenic functions, as well as for 
effective repurposing of existing drugs that may be employed 
to target these complexes or their related pathways. Together, 
Inhibitors of downstream mediators
and pathway
Rescue of the wild-type
p53 functions
i.e.
PRIMA-1
RETRA
NSC59984
Interference with mechanism
of mutp53 accumulation
i.e.
SAHA
HSP inhibitors
Oncogenic activity
of mutp53 complexes
Displacement of mutp53
binding with specific interactors
i.e.
KA2 decoy
Inhibitors of mutp53
activators
i.e.
Rottlerin
PIN1 inhibitors
i.e.
Statins/other mevalonate pathway
inhibitors
Proteasome inhibitors
Figure 3 Therapeutic approaches targeting mutant p53 (mutp53) protein complexes.
Notes: Pharmacological approaches aimed at disrupting mutp53 complexes represent an appealing strategy for cancer therapy. Such approaches involve stabilizing mutp53 
to restore its wild-type functions, reducing mutp53 levels by disrupting mechanisms of mutp53 accumulation, counteracting mutp53 activity by targeting specific mutp53 
modulators, preventing or disrupting oncogenic complexes with specific target proteins, and inhibiting mediators or pathways downstream of mutp53 protein complexes 
(see text for details).
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these approaches may develop into novel therapeutic strate-
gies for the treatment of tumors bearing mutp53.
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